MarketPulse

kidney cancer

3 articles
BenzingaBenzinga··Vandana Singh

Merck Tumbles 4% as Cancer Trial Fails, Though HIV Approval Offers Lifeline

Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.
MRKEXELFDA approvalclinical trial failure
BenzingaBenzinga··Prnewswire

IceCure's Kidney Cancer Data Shows Strong Promise Ahead of European Presentation

IceCure Medical reports positive 5-year results from ICESECRET trial, demonstrating 83.9% recurrence-free rates in kidney cancer patients using cryoablation technology.
ICCMclinical trialkidney cancer
The Motley FoolThe Motley Fool··James Halley

Telix Pharmaceuticals Eyes Growth With Nuclear Medicine Expansion

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.
TLXbiotechradiopharmaceuticals